<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01489228</url>
  </required_header>
  <id_info>
    <org_study_id>DNDi-CH-E1224-001</org_study_id>
    <nct_id>NCT01489228</nct_id>
  </id_info>
  <brief_title>Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease</brief_title>
  <official_title>Phase 2 Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Three Oral E1224 Dosing Regimens and Benznidazole for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drugs for Neglected Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Drugs for Neglected Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of E1224, a pro-drug of ravuconazole, in&#xD;
      individuals with chronic indeterminate Chagas disease recruited in research centres in Tarija&#xD;
      and Cochabamba, Bolivia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chagas disease (CD) ranks among the world's most neglected diseases. In Latin America, 21&#xD;
      countries are endemic for CD with an estimated 108 million people at risk of contracting the&#xD;
      disease. Estimates from the 1980s indicated that some 16 million to 18 million individuals&#xD;
      were infected. In the 1990s, after a series of multinational control initiatives, estimates&#xD;
      of the number of infected people were revised to 9.8 million in 2001. The estimated burden of&#xD;
      disease in terms of disability-adjusted life years (DALYs) declined from 2.7 million in 1990&#xD;
      to 586,000 in 2001. Recent estimates from Pan American Health Organization (PAHO, 2006)&#xD;
      indicate 7.54 million infected people and 55,185 new cases per year.&#xD;
&#xD;
      The only two medicines available - benznidazole (BZN) and nifurtimox (NFX) - are known to&#xD;
      cause serious toxicity with unsatisfactory cure rates, especially when used in adult chronic&#xD;
      CD patients.&#xD;
&#xD;
      Novel antifungal triazole derivatives have arisen as alternative treatments for CD. They&#xD;
      inhibit T. cruzi ergosterol biosynthesis, which is essential for parasite growth and&#xD;
      survival, and have pharmacokinetic properties suitable for the treatment of this disseminated&#xD;
      intracellular infection. Several triazole derivatives have been tested in animal models of&#xD;
      CD, including D08701, posaconazole, ravuconazole (RAV), albaconazole, and TAK-187. In&#xD;
      particular, RAV has previously been shown to have potent in vitro and in vivo activities,&#xD;
      inducing parasitological cure in mice with acute infections, including those caused by&#xD;
      benznidazole-resistant strains of T. cruzi. Suppressive activity was also seen in dog models.&#xD;
&#xD;
      E1224 is a water-soluble monolysine salt form of the RAV pro-drug. It is a broad-spectrum&#xD;
      triazole antifungal with in vitro activity against most Candida and Aspergillus species, some&#xD;
      non-Aspergillus species of filamentous fungi, Cryptococcus, dermatophytes, and fungi that&#xD;
      cause the endemic mycoses.&#xD;
&#xD;
      RAV was evaluated extensively in animal models and in human trials including Phase 2 safety&#xD;
      and efficacy trials in oropharyngeal and esophageal candidiasis and onychomycosis, and for&#xD;
      prevention of invasive fungal infections in hematopoietic stem cell transplant recipients.&#xD;
&#xD;
      With the benign safety profile and the encouraging results of animal studies and favorable&#xD;
      pharmacokinetics, E1224 is considered a priority candidate for clinical development for the&#xD;
      treatment of Chagas' disease.&#xD;
&#xD;
      The general objective of this phase II trial is to determine whether each of three different&#xD;
      dosing regimens of E1224 are efficacious and safe in eradicating T. cruzi parasitemia in&#xD;
      individuals with the chronic indeterminate form of CD, in comparison to placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serial negative qualitative Polymerase Chain Reaction (PCR) results (3 negative PCR results from 3 samples to be collected over 7 days) as a measure of parasitological cure at end of treatment</measure>
    <time_frame>Day 65 (end of treatment)</time_frame>
    <description>To determine whether at least one of three dosing regimens of orally administered E1224 is more efficacious than placebo in individuals with chronic indeterminate CD, by determining the number of patients who convert from positive to negative in serial, qualitative PCR test results</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Consistently negative serial qualitative PCR as a measure of sustained parasitological eradication</measure>
    <time_frame>4, 6 and 12 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Qualitative PCR as a measure of parasite eradication</measure>
    <time_frame>Day 8, 15, 36 , 65 and at 4, 6 and 12 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative PCR as a measure of change in parasite load over time</measure>
    <time_frame>Day 8, 15, 36, 65 and at 4, 6 and 12 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serological conversion to negative and changes in titers over time as measured by conventional and non-conventional serologies</measure>
    <time_frame>Day 65 and at 4, 6 and 12 months after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the levels of biomarkers over time: brain natriuretic peptide, troponin T, selected prothrombotic factors, lytic antibodies, apolipoprotein A1 and multiplex serodiagnostic assay</measure>
    <time_frame>Day 36 , 65 and at 4, 6 and 12 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC), Peak Plasma Concentration (Cmax), Minimum Plasma Concentration (Cmin), Clearance, Volume of Distribution , and Plasma Terminal Half-Life (t1/2) of ravuconazole and benznidazole</measure>
    <time_frame>Day 0 (pre-dose), Day 1 (after 1st dose), Day 2, Day 3, steady-state phase (D8-D50), at the end of treatment (D65) and at the 4 months follow-up visit</time_frame>
    <description>Samples for population pharmacokinetics parameters of ravuconazole and benznidazole will be collected at randomly selected time points on Days 1, 2 and 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of adverse events (clinical and laboratory)</measure>
    <time_frame>Up to 12 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events and/or adverse events leading to treatment discontinuation</measure>
    <time_frame>Up to 12 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early and late predictors of sustainable response to treatments</measure>
    <time_frame>Up to 12 months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of pharmacokinetic parameters with parasitological response, changes in biomarkers and safety outcomes</measure>
    <time_frame>Day 8, 15, 36, 65, and at 4, 6 months and 12 months follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Chronic Chagas Disease, Indeterminate</condition>
  <arm_group>
    <arm_group_label>High Dose E1224</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose (HD - 8weeks) Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose E1224</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Dose (LD - 8 weeks) Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Short Dose E1224</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Short Dose (SD - 4 weeks) Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (8 weeks) Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Benznidazol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BZN (Laboratório do Estado de Pernambuco -LAFEPE, tablet 100mg), 5 mg/Kg/day PO divided in two daily doses, for 60 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E1224</intervention_name>
    <description>100 mg tablets</description>
    <arm_group_label>High Dose E1224</arm_group_label>
    <arm_group_label>Low Dose E1224</arm_group_label>
    <arm_group_label>Short Dose E1224</arm_group_label>
    <other_name>E1224 (prodrug for active ingredient Ravuconazole)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benznidazole</intervention_name>
    <description>100mg tablets</description>
    <arm_group_label>Benznidazol</arm_group_label>
    <other_name>Benznidazole (N-benzil-2-nitro-1-imidazolacetamida)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Screening Criteria:&#xD;
&#xD;
          -  Age &gt;18 to &lt; 50 years&#xD;
&#xD;
          -  Weight &gt; 40 kg&#xD;
&#xD;
          -  Diagnosis of T. cruzi infection by conventional serology (a minimum of two out of&#xD;
             three positive tests [enzyme linked immunosorbent assay (ELISA), indirect&#xD;
             immunofluorescence (IIF), or hemagglutination inhibition (HAI)])&#xD;
&#xD;
          -  Signed, written informed consent form&#xD;
&#xD;
          -  No signs and/or symptoms of the chronic cardiac and/or digestive form of CD&#xD;
&#xD;
          -  No acute or chronic health conditions that may interfere with the efficacy and/or&#xD;
             safety evaluation of the study drug&#xD;
&#xD;
          -  No formal contraindication to BZN and E1224&#xD;
&#xD;
          -  No known history of hypersensitivity, allergic, or serious adverse reactions to the&#xD;
             study drugs&#xD;
&#xD;
          -  No history of CD treatment with BZN or NFX at any time in the past&#xD;
&#xD;
          -  No history of systemic treatment with itraconazole, ketoconazole, posaconazole,&#xD;
             isavuconazole, or allopurinol in the past&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of T. cruzi infection by serial qualitative PCR AND Conventional&#xD;
             serology&#xD;
&#xD;
          -  Women in reproductive age must have a negative serum pregnancy test at screening, must&#xD;
             not be breastfeeding, and consistently use and/or have partner consistently use an&#xD;
             adequate contraceptive method&#xD;
&#xD;
          -  Normal ECG at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Abnormal laboratory test values at screening for the following parameters: total White&#xD;
             Blood Cells (WBC) count, platelet count, alanine transaminase (ALT), aspartate&#xD;
             transaminase (AST), total bilirubin, or creatinine; or gamma-glutamyl transferase&#xD;
             (GGT)&#xD;
&#xD;
          -  History of alcohol abuse or any other drug addiction (as specified in the Study Manual&#xD;
             of Operations)&#xD;
&#xD;
          -  Any condition that prevents the patient from taking oral medication&#xD;
&#xD;
          -  Any concomitant use of antimicrobial or antiparasitic agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabela Ribeiro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Drugs for Neglected Diseases initiative</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Faustino Torrico, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Mayor San Simón. Cochabamba, Bolivia.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joaquim Gascón, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRESIB - Centre de Recerca en Salut Internacional de Barcelona, Spain.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fabiana P Alves, PhD</last_name>
    <phone>+552122152941</phone>
    <email>falves@dndi.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Plataforma de Atención Integral a los Pacientes con Enfermidad de Chagas</name>
      <address>
        <city>Cochabamba</city>
        <country>Bolivia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faustino Torrico, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Cristina Alonso, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Faustino Torrico, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Plataforma de Atención Integral a los Pacientes con Enfermidad de Chagas</name>
      <address>
        <city>Tarija</city>
        <country>Bolivia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lourdes Ortiz, MSc</last_name>
    </contact>
    <investigator>
      <last_name>Lourdes Ortiz, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Bolivia</country>
  </location_countries>
  <link>
    <url>http://www.dndi.org</url>
    <description>Drugs for Neglected Diseases initiative</description>
  </link>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>November 24, 2011</study_first_submitted>
  <study_first_submitted_qc>December 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2011</study_first_posted>
  <last_update_submitted>December 19, 2011</last_update_submitted>
  <last_update_submitted_qc>December 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chagas Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chagas Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzonidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

